Abstract LB358: Single cell RNA sequencing of cerebrospinal fluid lymphocytes in CARv3 TEAM E treated glioblastoma patients
Abstract Glioblastoma (GBM) is a devastating primary brain tumor of adults with few treatment options. While there has been long-standing interest in engaging the immune system to combat this disease, monoclonal antibody therapies – including checkpoint modulating agents – have yet to result in widespread clinically meaningful outcomes. By contrast, adoptive cell therapies including chimeric antigen receptor (CAR)-T cell therapies have demonstrated promising early indications of efficacy in select GBM patients. However, heterogeneity of target molecule expression remains a significant barrier to long-term disease control. In a recent report, a first-in-human trial of CARv3-TEAM-E T cells engineered to target the epidermal growth factor receptor variant III tumor-specific antigen (EGFRvIII) as well as wild-type EGFR through secretion of a T-cell-engaging antibody molecule (TEAM) showed preliminary evidence of CAR activity. We now report the results of single cell RNA-sequencing (scRNA seq) of lymphocytes isolated from the cerebrospinal fluid (CSF) of CARv3-TEAM-E treated GBM patients. Longitudinal CSF sampling in these patients was performed via an Ommaya reservoir. Sampled cells were interrogated by scRNA Seq. We demonstrate the ability to detect transduced CARv3-TEAM-E expressing T cells in the CSF from these patients. Unsupervised analysis revealed evidence of the expression of cytotoxic effector gene expression programs, which we explore over the course of longitudinal sampling in this initial cohort. Additionally, we compare expression signatures in the CSF-sampled T cells to those present in the CARv3-TEAM-E infusion products. Taken together, our findings offer insight into the longitudinal dynamics of T cell gene expression programs in the setting of this first-in-human trial of CARv3-TEAM-E T cells in GBM patients. Citation Format: Christopher Mount, Demi Gerovasilis, Sophia Kovatsis, Jun Zhong, Md Raihan Chowdhury, Maxx King, William T. Curry, Elizabeth R. Gerstner, Kathleen M. Gallagher, Bryan D. Choi, Mario Suva, Marcela V. Maus. Single cell RNA sequencing of cerebrospinal fluid lymphocytes in CARv3 TEAM E treated glioblastoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB358.
Authors
- Kathleen Gallagher (ORCID: https://orcid.org/0000-0002-6952-7885)
- Mario L. Suvà (ORCID: https://orcid.org/0000-0001-9898-5351)
- Maxx King
- Christopher Mount (ORCID: https://orcid.org/0000-0003-1635-2492)
- Marcela V. Maus (ORCID: https://orcid.org/0000-0002-7578-0393)
- Md. Raihan Chowdhury (ORCID: https://orcid.org/0000-0003-1085-1258)
- Bryan D. Choi (ORCID: https://orcid.org/0000-0002-5090-2470)
- William T. Curry (ORCID: https://orcid.org/0000-0002-8036-1847)
- Jun Zhong (ORCID: https://orcid.org/0009-0007-2813-6865)
- Elizabeth Robins Gerstner (ORCID: https://orcid.org/0000-0003-2382-3838)
- Sophia Kovatsis
- Demi Gerovasilis
Institutions
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1158/1538-7445.am2025-lb358
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00